title: Efficacy of Adding Dutasteride to α-Blocker Therapy Treated Benign Prostatic Hyperplasia Patients with Small Volume Prostate (<30 mL).
abstract: OBJECTIVE
  To assess the efficacy of dutasteride add-on therapy for patients with benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS) with small prostates who have been treated with α-blocker therapy for >3 months.
  
  
  METHODS
  A total of 110 men with clinical BPH were enrolled. There were 17 and 93 subjects with a prostate volume (PV) <30 and ≥30 mL, respectively. All subjects had been treated with α-blocker therapy for >3 months. Subjective and objective clinical variables were assessed using the total International Prostate Symptom Score (IPSS-T), IPSS quality of life (IPSS-QoL), IPSS voiding subscore (IPSS-V), IPSS storage subscore (IPSS-S), overactive bladder symptom score (OABSS), PV, prostate specific antigen (PSA) level, post-void residual (PVR), and maximum flow rate (Qmax). These variables were assessed at baseline and every 3 months for 1 year.
  
  
  RESULTS
  In the small prostate group, IPSS-T and IPSS-V showed improvements from baseline at 6 and 9 months, storage subscore at 6 months, and OABSS at 3 months, but no sustained improvements were observed. During the study period, only the IPSS QoL scores did not show any improvement. Conversly, dutasteride was significantly effective at improving IPSS-T, IPSS-V, IPSS-S, and IPSS-QoL scores throughout the study period in the large prostate BPH group. PSA levels and PV significantly decreased in both groups throughout the study.
  
  
  CONCLUSIONS
  Benign prostatic hyperplasia in LUTS patients with small prostates did not show a sustainable benefit from the addition of dutasteride to α-blocker therapy.
authors.affiliation: Department of Urology, Kinki University Faculty of Medicine, Osaka-Sayama, Japan.
authors.forename: Mamoru
authors.initials: M
authors.lastname: Hashimoto
authors.affiliation: Department of Urology, Kinki University Faculty of Medicine, Osaka-Sayama, Japan.
authors.forename: Nobutaka
authors.initials: N
authors.lastname: Shimizu
authors.affiliation: Department of Urology, Kinki University Faculty of Medicine, Osaka-Sayama, Japan.
authors.forename: Koichi
authors.initials: K
authors.lastname: Sugimoto
authors.affiliation: Department of Urology, Kinki University Faculty of Medicine, Osaka-Sayama, Japan.
authors.forename: Sachiko
authors.initials: S
authors.lastname: Hongoh
authors.affiliation: Department of Urology, Kinki University Faculty of Medicine, Osaka-Sayama, Japan.
authors.forename: Takafumi
authors.initials: T
authors.lastname: Minami
authors.affiliation: Department of Urology, Kinki University Faculty of Medicine, Osaka-Sayama, Japan.
authors.forename: Masahiro
authors.initials: M
authors.lastname: Nozawa
authors.affiliation: Department of Urology, Kinki University Faculty of Medicine, Osaka-Sayama, Japan.
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Yoshimura
authors.affiliation: Department of Urology, Nara Hospital Kinki University Faculty of Medicine, Ikoma, Japan.
authors.forename: Akihide
authors.initials: A
authors.lastname: Hirayama
authors.affiliation: Department of Urology, Mimihara General Hospital, Sakai, Japan.
authors.forename: Hideo
authors.initials: H
authors.lastname: Tahara
authors.affiliation: Department of Urology, Kinki University Faculty of Medicine, Osaka-Sayama, Japan.
authors.forename: Hirotsugu
authors.initials: H
authors.lastname: Uemura
mesh_terms: D058891:5-alpha Reductase Inhibitors / Q000008:administration & dosage*; D000284:Administration, Oral; D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage*; D000368:Aged; D002214:Capsules; D004359:Drug Therapy, Combination; D000068538:Dutasteride / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D009929:Organ Size; D011446:Prospective Studies; D011467:Prostate / Q000473:pathology; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000473:pathology; D011788:Quality of Life; D016896:Treatment Outcome
chemical_list: D058891:5-alpha Reductase Inhibitors; D000317:Adrenergic alpha-Antagonists; D002214:Capsules; D000068538:Dutasteride
keywords: benign prostatic hyperplasia; dutasteride; lower urinary tract symptoms; small prostate